A Study to Evaluate the Efficacy and Safety of TSL-1502 Capsules in Breast Cancer Patients With Germline BRCA Mutations
Clinical trial NCT05420779 · UNKNOWN
Trial details
- NCT number
- NCT05420779
- Sponsor
- Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-06-30
- Primary completion
- 2024-12-31
- Enrollment
- 125
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.